CFO
Menu
  • Accounting & Tax
  • Banking & Capital Markets
  • Growth Companies
  • Human Capital & Careers
  • Risk & Compliance
  • Strategy
  • Technology
  • Sign InSign Up
CFO
  • Conferences
  • Webcasts
  • Research
  • White Papers
  • Jobs
  • Training
  • Newsletters
  • Magazine
CFO
Companies Are Worried About Employee Retention, But Don’t Plan to Raise Pay
A study from PayScale found companies are hoping…
CEO Pay Ratio Rule Is ‘Disclosure by Soundbite’
New academic analysis pulls no punches, calling…
Luring Private Equity to Your Divestment Deal
Private equity bidders can accelerate a deal's…
  • Accounting & Tax
  • Banking & Capital Markets
  • Risk & Compliance
  • Human Capital & Careers
  • Growth Companies
  • Strategy
  • Technology
M&A

Merck to Buy French Animal Health Company

Merck announced a $2.37 billion deal for digital animal identification provider Antelliq.

William Sprouse
December 14, 2018 | CFO.com | US
share
Tweet
Print

Email this article

Merck & Co. reached a deal to acquire the French digital animal identification solutions company Antelliq Group for $2.37 billion from funds advised by BC Partners. The transaction is all cash. Merck said it would assume $1.3 billion in Antelliq’s debt, which it intends to repay shortly after closing.

Antelliq Group, which makes digital identification products for animals, had $406.5 million in sales for the year ended September 30. Merck’s animal health segment had sales of $3.88 billion in 2017.

Recommended Stories:
  • Navient Rejects $3.2 Billion Takeover Bid
  • J&J Buys Auris for $3B in Surgical Robotics Play
  • Luring Private Equity to Your Divestment Deal

Merck shares have risen 40% this year but fell 1% on the announcement.

The deal comes as investors see value in spinning off the animal health businesses like Merck’s rivals. Pfizer’s Zoetis raised $2.2 billion in an initial public offering in 2013. Elanco, the former animal health business at Lilly, raised $1.51 billion through an IPO in September.

In October, Merck’s CEO Kenneth Frazier said his company was a good owner of the animal health unit.

“Merck Animal Health is a leader in the animal health business and has delivered consistent above-market growth driven by a broad portfolio of innovative pharmaceuticals, vaccines, and other value-added technologies and services,” Frazier said in a statement.

“This acquisition is well aligned with our strategy to generate long-term growth and sustainable value for our customers and shareholders,” said Frazier.

Merck said the deal was expected to close in the second quarter of 2019. After closing, Antelliq will be a wholly owned and separately operated subsidiary within Merck’s animal health division.

“Antelliq is a unique business which played a pivotal role in driving forward the convergence of the animal intelligence and animal health industries globally,” Antelliq Chairman Jean-Baptiste Wautier said, adding that Merck was an ideal partner for Antelliq to support the next stage of its growth.

Photo: Antelliq

Post navigation

← 5 Health Care Trends for CFOs to Watch in 2019
Avon Calls for Ex-P&G Exec Arnal as New CFO →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Advertisement

Popular Articles

  1. The CFO’s Crucial Role in Digital Transformation
  2. Why Risk Management Should Be a Higher Priority
  3. Metric of the Month: Establishing the Daily Cash Position
  4. PwC Hires More Companies’ Tax Teams
  5. Investors Overreact to Restatements in the Short Term
Advertisement
 

Topics

  • Accounting & Tax
  • Banking & Capital Markets
  • Human Capital & Careers
  • Growth Companies
  • Risk & Compliance
  • Strategy
  • Technology

Media

  • Videos
  • Whitepapers
  • Research
  • Magazine

Events

  • Conferences
  • Argyle Events
  • Webcasts

Services

  • Reprints
  • Back Issues
  • Mobile
  • Widgets
  • RSS

About CFO

  • About CFO
  • Editorial Staff
  • Press
  • Advertise
  • Contact Us

Want the Magazine?

Relax and unplug with our award-winning coverage.

Subscribe Now
Follow Us